Discovery and structural chemistry
Mitragynine was first isolated from Mitragyna speciosa leaves in 1907 by E. M. Hooper, working in the early-20th-century tradition of chemical characterization of Asian botanicals that had drawn European interest. Full structural characterization including stereochemistry took several more decades; the molecule's complete three-dimensional structure was settled in the mid-20th century.
Structurally, mitragynine is an indole alkaloid — a class of nitrogen-containing organic compounds built around an indole ring system. The indole class includes many bioactive molecules: serotonin, the tryptamines, ergot alkaloids, reserpine. Mitragynine specifically belongs to the corynantheidine sub-family of indole alkaloids, characterized by a complex polycyclic structure that also appears in plants like yohimbe.
7-hydroxymitragynine is structurally identical to mitragynine except for an added hydroxyl (-OH) group at the 7 position. That small structural change produces a dramatic pharmacological one — see our alkaloid comparison guide.
Receptor pharmacology — why kratom isn't morphine
Mitragynine binds the mu-opioid receptor (the receptor most opioid analgesics target), but with two important differences from classical opioids:
1. Partial agonism
Mitragynine is a partial agonist at the mu-opioid receptor — it binds and activates the receptor, but produces less maximum response than a full agonist (like morphine) would, even at saturating doses. This is why mitragynine's analgesic effects plateau at higher doses and why it produces less respiratory depression than equipotent doses of morphine. Partial agonism is a mechanistically protective feature — it sets a ceiling on receptor activation that full-agonist opioids don't have.
2. Polypharmacology beyond opioid receptors
Mitragynine is also active at:
- Alpha-2 adrenergic receptors — agonism here produces alertness and focus effects similar to compounds like clonidine. This is one of the dominant mechanisms of kratom's low-dose stimulant character.
- Serotonin receptors (5-HT2A, 5-HT2C, others) — contributes to mood effects.
- Calcium channels — modulation likely contributes to smooth-muscle relaxant effects observed at higher doses.
- Delta and kappa opioid receptors — additional opioid receptor activity that contributes to the overall effect profile.
This polypharmacology is why kratom produces a dose-dependent stimulant-to- sedative shift — at low doses adrenergic effects dominate; at higher doses opioid receptor effects dominate. Classical opioids without the adrenergic component don't produce this curve.
The 7-OH metabolism connection
One of the most underappreciated aspects of kratom pharmacology: your liver converts a portion of consumed mitragynine to 7-hydroxymitragynine in vivo. This means even when you consume natural-leaf kratom with very low 7-OH content (well under 2% of total alkaloids), your body produces additional 7-OH from the mitragynine fraction.
The conversion happens via cytochrome P450 enzymes in the liver, primarily CYP3A4 and CYP2D6 — the same enzymes that metabolize many prescription medications, which is why kratom can have drug interactions even with drugs that don't share kratom's receptor targets.
The clinical implication: natural kratom's analgesic effects are bigger than the leaf's small 7-OH content would predict, because additional 7-OH is generated metabolically. This is also why people who genetically have higher CYP2D6 activity ("ultra-rapid metabolizers") may experience stronger or different kratom effects than slow metabolizers.
Half-life and elimination
Mitragynine's elimination half-life in humans is approximately 23–24 hours (published research; varies by individual metabolism). Practical implications:
- Daily use produces accumulation — each day's dose adds to residual alkaloid from the previous day until steady-state is reached around 5–7 days
- Clearance after cessation is slow — substantial mitragynine remains in tissue for several days after the last dose, which is why tolerance breaks need to be at least 7 days to start producing meaningful receptor reset
- Detection windows are days, not hours — see our drug-test guide
Why concentration matters more than gram-weight
Effects scale with the amount of mitragynine you consume — not the weight of the kratom product. Three product profiles delivering the same ~60 mg mitragynine dose:
- 5 grams of 1.2% mitragynine leaf — bulky, slow consumption
- 0.5 grams of 12% mitragynine extract — small volume, similar dose
- 1 mL of typical 6% liquid extract — also approximately equivalent
Same alkaloid load, very different volumes. The mitragynine percentage on the Certificate of Analysis is what tells you how concentrated the product is — and therefore how to dose it. See our why extracts aren't just stronger kratom for more on the concentration spectrum.
What you can do with this
- Always look at the mitragynine percentage on the COA — not just the gram-weight of the product
- For natural-leaf products, expect mitragynine to be the dominant alkaloid with 7-OH well below 2% of total alkaloids — anything else is a synthetic concentrate
- Account for the slow half-life when planning daily use, tolerance breaks, and dose timing
- Be aware of CYP-mediated drug interactions, particularly with medications metabolized by CYP3A4 and CYP2D6
For deeper background
See our companion articles:
Frequently Asked Questions
What exactly is mitragynine?
Mitragynine is an indole alkaloid — a nitrogen-containing organic compound — produced by the kratom tree (Mitragyna speciosa). It is the dominant psychoactive compound in kratom leaf, comprising 60–70% of the total alkaloid content and roughly 1–2% of dried leaf by mass. Pharmacologically it's a partial agonist at mu-opioid receptors with additional activity at adrenergic, serotonin, and other receptor systems — the polypharmacology that produces kratom's distinctive dose-dependent effect curve.
When was mitragynine discovered?
Mitragynine was first isolated from kratom leaves by Dutch chemist E. M. Hooper in 1907, and its structure was confirmed by D. Hooper and others in subsequent decades. The full structural characterization, including stereochemistry, was completed in the mid-20th century. Despite this long scientific history, mitragynine remained relatively obscure in Western pharmacology until kratom's commercial expansion in the 2000s drove renewed research interest.
How does mitragynine compare to morphine?
Mitragynine is a much weaker mu-opioid receptor agonist than morphine on a per-molecule basis, and notably it's a partial agonist rather than a full agonist. This means mitragynine produces less maximum receptor activation than morphine even at saturating doses — which is one reason it produces a meaningfully different effect profile (less respiratory depression risk at typical doses, dose-dependent shift from stimulation to sedation). 7-hydroxymitragynine, kratom's minor alkaloid, is much more potent at the same receptor — roughly 10–13x morphine — but it's present in only trace amounts in natural leaf.
What does mitragynine do at receptors other than opioid?
Three additional receptor systems are well-documented. (1) Alpha-2 adrenergic agonism — produces the alertness and focus effects characteristic of low-dose kratom; similar to compounds like clonidine. (2) Serotonin receptor activity (5-HT2A and 5-HT2C among others) — contributes to mood effects. (3) Calcium channel modulation — likely contributes to the smooth-muscle relaxant effects observed at higher doses. The polypharmacology is part of why kratom's effect profile differs so noticeably from classical opioids despite the shared mu-opioid receptor activity.
How is mitragynine metabolized in the body?
Mitragynine is metabolized primarily in the liver via the cytochrome P450 enzyme system (especially CYP3A4 and CYP2D6). One important metabolic product is 7-hydroxymitragynine — meaning that even when you consume natural-leaf kratom with low 7-OH content, your liver produces additional 7-OH from mitragynine. This in-vivo conversion is part of why natural kratom has analgesic effects beyond what the leaf's small 7-OH content would predict. The half-life of mitragynine in humans is approximately 23–24 hours, so the substance accumulates with daily dosing and clears slowly over days.
Why does mitragynine concentration matter so much?
Because effects scale with the amount of mitragynine you consume, not the gram-weight of the kratom product. A 5-gram dose of 1.2% mitragynine leaf delivers ~60 mg mitragynine. A 0.5-gram dose of 12% mitragynine extract delivers the same ~60 mg. Same alkaloid load, very different volume. Concentration determines the dose window, the side-effect threshold, and how easy it is to accidentally overshoot. This is why reading the mitragynine percentage on a Certificate of Analysis matters more than any other label feature.